logo-loader

Theralase's technology lauded in new scientific study

Last updated: 09:59 29 Jun 2017 EDT, First published: 04:59 29 Jun 2017 EDT

Laser treatment in the lab
LILT wavelength selection depends on the arthritic condition being treated.

Medical journal ‘Lasers in Medical Science’ has published an article on the effectiveness of Theralase Technologies Inc.'s (CVE:TLT, OTCMKTS:TLTFF) laser technology in treating arthritis.

OK, the article refers to the use of the therapeutic laser technology in the treatment of mice, but we are all familiar with the concept of testing medical innovations on rodents, which comprise 95% of all animals used in laboratory tests.

The genetic, biological and behavior characteristics of mice and rats closely resemble those of humans, and in this particular instance FVB mice were used.

The latest study, entitled "Low-intensity laser therapy efficacy evaluation in FVB mice subjected to acute and chronic arthritis", was authored by Joao Paulo Mardegan Issa, Bianca Ferreira Trawitzki, Edilson Ervolino, Ana Paula Macedo and Lothar Lilge.

Low-intensity laser therapy (LILT) was evaluated on the following criteria: clinical symptoms, histological analysis of inflammatory infiltrate and damage to the articular surfaces.

The results demonstrated that LILT wavelength selection depends on the arthritic condition being treated. Superpulsed 905 nm laser light demonstrated better results for an anti-inflammatory effect in acute arthritis, while 660 nm laser light showed better results in chronic arthritis.

For acute inflammation, a single treatment using lasers with an intermediate or long wavelength was sufficient to promote an anti-inflammatory effect and control articular resorption (joint degeneration); double treatment on sequential days in cases of acute inflammation was not beneficial, the study found.

For chronic inflammation, a treatment plan comprising three sessions with an interval of one day between them was sufficient to eliminate the clinical signs and to control articular resorption.

Roger Dumoulin-White, president and chief executive officer of Theralase, noted that the Theralase therapeutic technology uses both superpulsed 905 and 660 nm laser light wavelengths.

“The publication also supports Theralase's methodology of treating patients every other day,” the Theralase boss added.

It is this type of pre-clinical research that helps increase the adoption of Theralase laser therapy by mainstream medicine to allow healthcare practitioners the opportunity to effectively treat a devastating disease such as arthritis, he observed.

Theralase Technologies shares update on Phase II Bladder Cancer study

Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive Bladder Cancer clinical study during an interview with Steve Darling from Proactive. DuMoulin-White shared the significant findings from...

on 01/16/2024